Who develops the clinical protocol for a study in a pharmaceutical company?

Who develops the clinical protocol for a study in a pharmaceutical company?

• A. Medical affairs team
• B. Regulatory affairs team
• C. Pharmacovigilance team
• D. Public relations team

Answer: (A)

The clinical protocol is the master plan that lays out why the study is being done, how it will be designed, what endpoints will be measured, who can participate, and how safety will be monitored. The medical affairs team is the best fit to develop this, because they bring the medical and scientific perspective needed to ensure the study addresses meaningful patient outcomes and fits the therapeutic strategy. They coordinate with clinical development, biostatistics, and regulatory to ensure the protocol is scientifically sound, feasible, and aligned with regulatory expectations. They also shape the clinical rationale and ensure the plan supports later medical communications and publications. Regulatory affairs handles regulatory compliance and submissions, pharmacovigilance focuses on safety monitoring and risk management within the protocol, and public relations deals with communications—areas that do not drive the core clinical design the way medical affairs does.

The clinical protocol is the master plan that lays out why the study is being done, how it will be designed, what endpoints will be measured, who can participate, and how safety will be monitored. The medical affairs team is the best fit to develop this, because they bring the medical and scientific perspective needed to ensure the study addresses meaningful patient outcomes and fits the therapeutic strategy. They coordinate with clinical development, biostatistics, and regulatory to ensure the protocol is scientifically sound, feasible, and aligned with regulatory expectations. They also shape the clinical rationale and ensure the plan supports later medical communications and publications. Regulatory affairs handles regulatory compliance and submissions, pharmacovigilance focuses on safety monitoring and risk management within the protocol, and public relations deals with communications—areas that do not drive the core clinical design the way medical affairs does.